Insights Into EGFR-Mutant NSCLC 2022
Perspectives on genetic testing practices, initial management, and sequencing of therapies in EGFR-mutant NSCLC
Central – March 29, 2022
Faculty Chair
Narjust Duma, MD
Dana-Farber Brigham Cancer Center, Boston, MA, USA
Southeast – May 17, 2022
Faculty Chair
Stephen Liu, MD
Georgetown University, Washington, DC, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
REPORT SNAPSHOT
- A moderated roundtable discussion with community oncologists from the Central region of the United States was held virtually on March 29, 2022
- Disease-state and data presentations were led by Dr Narjust Duma, from Dana-Farber Brigham Cancer Center, in conjunction with content developed by the Aptitude Health clinical team
- Insights were obtained on the management and current use of treatment options of EGFR-mutant NSCLC among community physicians
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion
- The group of advisors comprises 11 oncologists from the Central region of the United States
